Cargando…
Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention
Radiation is the most potent mode of cancer therapy; however, resistance to radiation therapy results in tumor relapse and subsequent fatality. The cancer stem cell (CSC), which has better DNA repair capability, has been shown to contribute to tumor resistance and is an important target for treatmen...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002480/ https://www.ncbi.nlm.nih.gov/pubmed/27597870 http://dx.doi.org/10.1155/2016/5785786 |
_version_ | 1782450575637479424 |
---|---|
author | Pranatharthi, Annapurna Ross, Cecil Srivastava, Sweta |
author_facet | Pranatharthi, Annapurna Ross, Cecil Srivastava, Sweta |
author_sort | Pranatharthi, Annapurna |
collection | PubMed |
description | Radiation is the most potent mode of cancer therapy; however, resistance to radiation therapy results in tumor relapse and subsequent fatality. The cancer stem cell (CSC), which has better DNA repair capability, has been shown to contribute to tumor resistance and is an important target for treatment. Signaling molecules such as Notch, Wnt, and DNA repair pathways regulate molecular mechanisms in CSCs; however, none of them have been translated into therapeutic targets. The RhoGTPases and their effector ROCK-signaling pathway, though important for tumor progression, have not been well studied in the context of radioresistance. There are reports that implicate RhoA in radioresistance. ROCK2 has also been shown to interact with BRCA2 in the regulation of cell division. Incidentally, statins (drug for cardiovascular ailment) are functional inhibitors of RhoGTPases. Studies suggest that patients on statins have a better prognosis in cancers. Data from our lab suggest that ROCK signaling regulates radioresistance in cervical cancer cells. Collectively, these findings suggest that Rho/ROCK signaling may be important for radiation resistance. In this review, we enumerate the role of Rho/ROCK signaling in stemness and radioresistance and highlight the need to explore these molecules for a better understanding of radioresistance and development of therapeutics. |
format | Online Article Text |
id | pubmed-5002480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-50024802016-09-05 Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention Pranatharthi, Annapurna Ross, Cecil Srivastava, Sweta Stem Cells Int Review Article Radiation is the most potent mode of cancer therapy; however, resistance to radiation therapy results in tumor relapse and subsequent fatality. The cancer stem cell (CSC), which has better DNA repair capability, has been shown to contribute to tumor resistance and is an important target for treatment. Signaling molecules such as Notch, Wnt, and DNA repair pathways regulate molecular mechanisms in CSCs; however, none of them have been translated into therapeutic targets. The RhoGTPases and their effector ROCK-signaling pathway, though important for tumor progression, have not been well studied in the context of radioresistance. There are reports that implicate RhoA in radioresistance. ROCK2 has also been shown to interact with BRCA2 in the regulation of cell division. Incidentally, statins (drug for cardiovascular ailment) are functional inhibitors of RhoGTPases. Studies suggest that patients on statins have a better prognosis in cancers. Data from our lab suggest that ROCK signaling regulates radioresistance in cervical cancer cells. Collectively, these findings suggest that Rho/ROCK signaling may be important for radiation resistance. In this review, we enumerate the role of Rho/ROCK signaling in stemness and radioresistance and highlight the need to explore these molecules for a better understanding of radioresistance and development of therapeutics. Hindawi Publishing Corporation 2016 2016-08-15 /pmc/articles/PMC5002480/ /pubmed/27597870 http://dx.doi.org/10.1155/2016/5785786 Text en Copyright © 2016 Annapurna Pranatharthi et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Pranatharthi, Annapurna Ross, Cecil Srivastava, Sweta Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention |
title | Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention |
title_full | Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention |
title_fullStr | Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention |
title_full_unstemmed | Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention |
title_short | Cancer Stem Cells and Radioresistance: Rho/ROCK Pathway Plea Attention |
title_sort | cancer stem cells and radioresistance: rho/rock pathway plea attention |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002480/ https://www.ncbi.nlm.nih.gov/pubmed/27597870 http://dx.doi.org/10.1155/2016/5785786 |
work_keys_str_mv | AT pranatharthiannapurna cancerstemcellsandradioresistancerhorockpathwaypleaattention AT rosscecil cancerstemcellsandradioresistancerhorockpathwaypleaattention AT srivastavasweta cancerstemcellsandradioresistancerhorockpathwaypleaattention |